Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study

Reasons for Discontinuing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes in Real-World Settings: The KAMOGAWA-A Study

Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a class of antidiabetic agents known to exert cardioprotective, renoprotective, and hypoglycemic effects. However, these agents have been associated with adverse effects, such as genital infection, volume depletion, hypoglycemia, and diabetic k...

Full description

Bibliographic Details
Main Authors: Yuto Saijo, Hiroshi Okada, Shinnosuke Hata, Hanako Nakajima, Nobuko Kitagawa, Takuro Okamura, Takafumi Osaka, Noriyuki Kitagawa, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Masahide Hamaguchi, Michiaki Fukui
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Journal of Clinical Medicine
Subjects:
sodium-glucose cotransporter 2 (SGLT2) inhibitors
diabetes
drug discontinuation
Online Access:https://www.mdpi.com/2077-0383/12/22/6993

Similar Items

Similar Items